IMM

1.61%

31.5¢ immutep limited

Ann: Immutep receives EMA scientific advice for Phase 3 in MBC, page-20

First 20 Last

Share
Profile

Follow
Runaway2020

394 Posts.

47

29/10/21

14:11

Post #: 57181708
Share

Originally posted by tuts: ↑

While a possibility, my short answer is No! It is highly improbable we get "commercialisation-for-clinical use" green tick, which is in the hands of the gods to be, EMA/FDA. Good AIPAC data will help our fast track status and not need to go through comprehensive hoops with NDA (new drug application) and it may create a possibility of "provisional approval" (for commercial use) from FDA BUT REGARDLESS, clinical trials will still need to be completed, if anything, the company will be "under watch" and provisional approval will be cancelled if clinical trials are not completed. In saying that, depending on a number of factors; type of disease, how un-met it is, how good the drug is, etc, there are considerations as part of fast tracking and provisional approval to reduce the size of the phase (e.g., phase III in this case and potentially future Ph II in our other trials). All of this means about 2 years faster in commercialisation ...

You can hopefully see, we cannot fund phase III by way of commercialisation for our first cab off the rank, Efti.

in saying all that, mate, I can tell you, if we get good data with AIPAC & TACTI alone, not to mention other our trials, we will not have to worry about funding ... IF ANYTHING, I WOULD LOVE for shareholders to fund it as part of a SPP for example ... it will GIVE US, AND NOT PREDATORS, THE OPPORTUNITY TO HAVE A SLICE OF A GREAT COMPANY.

But we need data, and we need to wait on that ... it is coming, hopefully good, as we anticipate and as indications are, specially with today's news.

Expand

Thanks tuts makes sense. Here is hoping for better than average data.
I, like you and a few others hope there is no TO but that I suppose is in the lap of the top 5 SH.
Love ya work cheers

Last edited by Runaway2020: 29/10/21

IMM Price at posting: 56.5¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BUX

Buxton projects new graphite province discovery at WA Narryer play

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 5 more messages in this thread...

First 20 Last

Add IMM (ASX) to my watchlist

(20min delay)
Last 31.5¢		Change 0.005(1.61%)		Mkt cap ! $458.1M

Open	High	Low	Value	Volume
31.0¢	31.5¢	30.5¢	$251.5K	806.4K

Buyers (Bids)

No.	Vol.	Price($)
11	121215	31.0¢

Sellers (Offers)

Price($)	Vol.	No.
31.5¢	2864	3

View Market Depth

No.	Vol.	Price($)
11	121215	0.310
21	282998	0.305
21	464160	0.300
6	89833	0.295
11	293135	0.290

Price($)	Vol.	No.
0.315	2864	3
0.320	175639	5
0.325	392741	5
0.330	168348	4
0.335	196676	5

Last trade - 16.10pm 04/10/2024 (20 minute delay)

IMM (ASX) Chart

Ann: Immutep receives EMA scientific advice for Phase 3 in MBC, page-20

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Immutep receives EMA scientific advice for Phase 3 in MBC, page-20

Top Stories

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News